Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03183102 · ClinicalTrials.gov registry record · NA

The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.

A NA study of Menopause, sponsored by Colorado State University.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03183102: Completed NA study of Menopause, sponsored by Colorado State University.

NCT03183102 is a NA study of Menopause that has completed, run by Colorado State University. The registered enrollment target is 30 participants, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03183102, a NA study of Menopause, has completed, sponsored by Colorado State University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pilot study is to determine if suppressing estrogen in premenopausal women results in changes in gut microbiota and if dietary flaxseed modulates these changes.

Primary Outcome

16s rRNA sequencing--Illumina MiSeq

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Flaxseed

Study Locations (1)

Colorado

  • Colorado State University - Fort Collins

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-10-01
Est. Completion 2022-12-30
Phase NA
Colorado State University

94 total trials

What the finished NCT03183102 record still lists

NCT03183102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Menopause appearing as the primary indexed condition, and to 1 intervention - of which Flaxseed is the first listed.

NCT03183102 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT03183102 about?

NCT03183102 is a clinical study titled "The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.". The purpose of this pilot study is to determine if suppressing estrogen in premenopausal women results in changes in gut microbiota and if dietary flaxseed modulates these changes.

What is the current status of trial NCT03183102?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-10-01. Estimated completion is 2022-12-30.

What conditions does trial NCT03183102 study?

This clinical trial studies the following conditions: Menopause.

What interventions are being tested in trial NCT03183102?

The interventions under investigation include: Flaxseed (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03183102?

This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03183102 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03183102's enrollment target sits among peer trials

30 41st of 54 higher than 11 of 54 other Menopause trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03183102, the US trial registry maintained by the National Library of Medicine. NCT03183102 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.